Active Ingredient(s): Oritavancin Diphosphate
FDA Approved: * March 12, 2021
Pharm Company: * MELINTA THERAP
Category: Antibiotics

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Kimyrsa Overview

Oritavancin, sold under the brand name Orbactiv among others, is a semisynthetic glycopeptide antibiotic medication for the treatment of serious Gram-positive bacterial infections. Its chemical structure as a lipoglycopeptide is similar to vancomycin.[4] The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved oritavancin for treatment of acute bacterial skin and skin structure infections.[5][3] Conten...

Read more Kimyrsa Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Kimyrsa Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Oritavancin Diphosphate
  • Powder: 1.2gm/vial, 400mg/vial
  • Powder, For Injection Solution, Lyophilized Powder: 1200 Mg.
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Kimyrsa: (1 result)

Sorted by National Drug Code
  • 70842-225 Kimyrsa 1200 mg/40ml Intravenous Injection, Powder, Lyophilized, for Solution by Melinta Therapeutics, LLC

Other drugs which contain Oritavancin Diphosphate or a similar ingredient: (2 results)